Stock Spotlight Archives - Page 101 of 388

ThursdayAug 18, 2022 2:11 pm

QualityStocksNewsBreaks – Advanced Container Technologies Inc.’s (ACTX) GrowPods Ideally Poised to Turn Tide Against Food Insecurity

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of GrowPods, environmentally controlled micro-farms that allow cultivation of ultra-clean crops all year long, believes its products may be part of the solution to eradicate food insecurity and malnutrition. The World Food Program’s (“WFP”) vision for 2030 “calls for the world to eradicate food insecurity and malnutrition and for national and global actors to partner together to achieve several goals, including providing access to food and sustainable food systems. According to WFP, turning the tide against hunger includes, in part, ‘sustainable consumption and production to reduce food loss and waste,’” a…

ThursdayAug 18, 2022 12:57 pm

QualityStocksNewsBreaks – GeoSolar Technologies Inc. Leveraging SmartGreen(TM) to Address Systemically Unsustainable Growth in Energy Demand

GeoSolar Technologies (“GST”), a Colorado-based climate technology company, has sought to address the systemically unsustainable growth in energy demand through the creation of its proprietary SmartGreen(TM), a system designed to harness energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels. Recent summer heatwaves have caused soaring temperatures that have increased the demand for ways to stay cool. “According to the International Energy Agency, the stock of global air conditioners is set to rise by 163% to over 5.5 billion units by 2050. In fact, the new electricity demand posed by…

WednesdayAug 17, 2022 2:35 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Capable of Delivering APIs More Efficiently by Overcoming Food Effect

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the allowance of a new patent in Japan, the fourth to be granted in that country and the 26th worldwide. “Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (‘THC’). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (‘APIs’) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing…

WednesdayAug 17, 2022 2:16 pm

QualityStocksNewsBreaks – Energy Fuels Inc.’s (NYSE American: UUUU) (TSX: EFR) White Mesa Mill ‘Meets Definition of Domestic Clean-Energy Infrastructure’

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based producer of uranium and vanadium and an emerging producer of rare earth elements (“REE”) products. “After concerns surfaced about the impact a Utah uranium mill [Energy Fuel’s White Mesa Mill] might have on the surrounding water sources, an op-ed piece in the Denver Post reported that there is ‘no evidence that implies the tailings cells are leaking or contaminating groundwater.’ That assessment aligns with what Energy Fuels has said all along; safety and environmental protection are top priorities for the company,” a recent article reads. The piece contains excerpts…

WednesdayAug 17, 2022 1:49 pm

QualityStocksNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Driving State-of-the-Art Solutions

Cepton (NASDAQ: CPTN) is an innovator pioneering high-performance Micro Motion Technology (“MMT(R)”) lidar solutions. The company recently selected Fabrinet (NYSE: FN), a leader specializing in precision optical, electro-optical, sophisticated electronic PCBA, and electro-mechanical process technologies, to produce its flagship automotive-grade Vista(R)-X90 lidar. The partnership could expedite Cepton’s efforts toward mass-market commercialization of high-performance, high-quality lidar solutions. “The Vista(R)-X90 lidar features Cepton’s patented MMT(R) technology configured to deliver scalable lidar solutions with a superior balance between performance, reliability and cost, as well as Cepton’s proprietary lidar engine ASIC, designed for optical illumination control, detection and signal processing. Vista(R)-X90 will be deployed…

MondayAug 15, 2022 12:39 pm

QualityStocksNewsBreaks – Cub Crafters Inc. Appealing to Personal Adventure Enthusiasts with Best-of-Class Backcountry Airplanes

Cub Crafters (typically styled CubCrafters) is the leading designer and manufacturer of light-sport, experimental and Part 23 certified backcountry aircraft. “Yakima, Washington-based CubCrafters has spent decades appealing to those who want to fly themselves by designing, building, testing, and selling best-of-class backcountry airplanes modeled on the classic Piper PA-18 Super Cub light aircraft, and the company’s own Cub-derived newly manufactured designs. CubCrafters offers various models of aircraft that fit under FAA Certified (Part 23), Light Sport Aircraft (‘LSA’), and Experimental Amateur Built (‘E/A-B’) classifications. CubCrafters sells finished aircraft as well as aircraft kits for experimental plane enthusiasts who enjoy the…

FridayAug 12, 2022 2:53 pm

QualityStocksNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre- and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. ‘These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its…

FridayAug 12, 2022 1:29 pm

QualityStocksNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses

Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this medical problem “through the creation of immune reprogramming technologies, which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases) and allergens,” a recent article reads. “While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s…

FridayAug 12, 2022 1:08 pm

QualityStocksNewsBreaks – Friendable Inc.’s (FDBL) 360-Degree Offering Promoting Artists’ Independence, Revenue Generation

Friendable (OTC: FDBL), a mobile technology and marketing company, announced its acquisition of Artist Republik and FeaturedX in January 2022, bringing together a 360-degree suite of services for artists. The acquisition completed the company’s flagship offering, Fan Pass Live. “Artists can now sign up for the Fan Pass Live artist platform and benefit from music production, distribution and marketing services without the control of music labels pulling the strings or eating up revenue… The 360-degree suite of Fan Pass Live, Artist Republik and FeaturedX promotes being an independent label in an artist’s pocket, meaning there are no gatekeepers, no middleman,…

FridayAug 12, 2022 12:40 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success

CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. Recently, the company announced that the FDA had approved an amendment to the study’s protocol, boosting its Berubicin clinical development program. “The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy,” explains a recent article. “The key objectives of the amendment, according to CNS Pharmaceuticals…

Site Search

Company Search

Category: Stock Spotlight